Quick Summary

Gastrodia elata is a traditional Chinese medicinal herb with a long history of use predominantly for neurological disorders. It contains bioactive compounds such as gastrodin and parishins that have demonstrated antioxidant, anti-inflammatory, neuroprotective, and metabolic regulatory properties in preclinical studies. Gastrodia has been investigated in various conditions including migraine, cerebral ischemia-reperfusion injury, Parkinson’s disease, epilepsy, and cognitive impairment. Despite promising preclinical and some clinical evidence, further rigorous human trials are needed to confirm its efficacy and safety.

What is it?

Gastrodia elata is a perennial herbaceous plant used in Traditional Chinese Medicine (TCM). Its tuber is the main medicinal part and is valued for its potential effects on the nervous system. The herb is also known as Tianma in TCM and has been incorporated into various traditional formulas targeting neurological health.

Traditional Uses

  • Treatment of headaches and migraines
  • Management of dizziness and vertigo
  • Support for neurological conditions including epilepsy and stroke recovery
  • Improvement of cognitive function post-stroke
  • General neuroprotective agent in TCM practice

Active Compounds

Major bioactive constituents of Gastrodia elata include:

  • Gastrodin – a phenolic glycoside reputed for neuroprotective and antioxidant effects
  • Parishins – compounds with potential anti-aging and metabolic regulatory properties
  • Additional phenolic compounds contributing to anti-inflammatory and neuroactive activities

Potential Benefits with Evidence Levels

  • Migraine management: Moderate evidence. A meta-analysis of 16 randomized controlled trials (RCTs) involving 1332 subjects found gastrodin to be significantly effective and safe for reducing migraine severity, frequency, and duration. (PMID: 36090869)
  • Cerebral ischemia-reperfusion injury (stroke): Limited to moderate evidence from preclinical and some clinical data. Gastrodin may modulate oxidative stress, inflammation, apoptosis, neurotransmission, and support blood-brain barrier integrity in stroke models. (PMID: 40458797, PMID: 40822475, PMID: 41451367)
  • Neuroprotection and Parkinson’s disease: Preclinical and limited clinical evidence suggest gastrodin and Gastrodia extracts may exert neuroprotective effects via multiple mechanisms; clinical confirmation is limited. (PMID: 40410612, PMID: 40868260)
  • Epilepsy treatment: Limited clinical evidence mainly from combination therapies. Herbal medicine with Gastrodia elata plus acupuncture showed reduced treatment failure risk and fewer adverse events in pediatric epilepsy cases. (PMID: 38723054)
  • Improvement of cognitive impairment post-stroke: Preliminary clinical and mechanistic insights support use of TCM formulas containing Gastrodia for cognitive recovery after stroke. (PMID: 40898703)
  • Skin protection against UVB damage: Animal model evidence shows fermented Gastrodia elata may alleviate UVB-induced skin injury through antioxidant and immune-modulatory effects. (PMID: 41596104)
  • Anti-aging effects: Animal studies indicate parishin extracts can reduce aging markers and improve cognitive and muscle functions in aged mice. (PMID: 41948381)
  • Gut microbiota modulation in neurodegenerative diseases and insomnia: Preclinical and review data suggest Gastrodia-containing formulations may influence gut microbiota to affect neurological disorders and sleep quality. (PMID: 41749438)
  • Adjunct in traumatic brain injury: Systematic reviews of RCTs report that Chinese herbal preparations including Gastrodia-containing formulas improved neurological function and reduced inflammatory biomarkers in traumatic brain injury patients. (PMID: 41438511)

Side Effects

Reported adverse events in clinical studies are minimal and generally comparable to control groups. No severe adverse events or major safety concerns have been documented. Detailed side-effect profiles remain sparse.

Drug Interactions

No specific documented drug interactions have been identified in the available literature. However, due to Gastrodia’s influence on neurotransmitter systems and inflammation pathways, theoretical interactions may exist and warrant caution. Clinical studies on herb-drug interactions are needed.

Who Should Avoid It

Currently, there are no well-established contraindications for Gastrodia elata. Nonetheless, caution is advised for certain populations due to limited safety data. Individuals who are pregnant or breastfeeding should consult healthcare professionals before use, given insufficient evidence on safety in these groups.

Evidence Limitations

  • Most studies are preclinical or conducted in animal models, with limited robust human clinical trials.
  • Clinical studies often have small sample sizes, varying methodologies, and heterogeneous designs.
  • Lack of standardized dosing, formulations, and preparations hinders comparability between studies.
  • High-quality randomized controlled trials are needed to confirm efficacy and safety in specific indications.
  • Pharmacokinetic and pharmacodynamic profiles in humans remain unclear, especially in special populations.
  • Long-term safety, detailed adverse effects, and potential herb-drug interactions remain insufficiently characterized.

References

Last Reviewed

June 2024

Disclaimer: This information is for educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any new herbal supplement, especially if you have underlying health conditions or are taking other medications.